626248-56-4

Usage

Uses

Used in Pharmaceutical Research:
3-(2H-1,2,3-Trizazol-2-yl)aniline is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its incorporation into drug molecules is driven by its biological properties, such as antitumor activity, which can be harnessed to develop new therapeutic agents for the treatment of cancer.
Used in Agrochemical Research:
In the agrochemical industry, 3-(2H-1,2,3-Trizazol-2-yl)aniline is employed as a component in the development of new pesticides and other agrochemicals. Its antimicrobial properties make it a valuable asset in creating effective solutions to combat microbial threats in agriculture.
Used in Materials Science:
3-(2H-1,2,3-Trizazol-2-yl)aniline also finds applications in the field of materials science. It is used in the design and synthesis of functionalized polymers and coordination compounds. The triazole ring's ability to form stable complexes makes it suitable for creating materials with specific properties, such as enhanced stability or reactivity.
Overall, 3-(2H-1,2,3-Trizazol-2-yl)aniline is a multifaceted chemical entity with broad applications across different industries, primarily due to its unique structural features and biological activities.

InChI:InChI=1S/C8H8N4/c9-7-2-1-3-8(6-7)12-10-4-5-11-12/h1-6H,9H2

Upstream product

• 288-36-8 1,2,3-triazole 
• 626-01-7 3-Iodoaniline 
• 342623-98-7 2-(3-nitrophenyl)-2H-1,2,3-triazole 
• 402-67-5 3-fluoro-1-nitrobenzene 
• 51039-49-7 2-phenyl-2H-[1,2,3]triazole 

Downstream Products

• 1374969-96-6 2-(3-(2H)-1,2,3-triazol-2-yl)phenylamino-6-chloro-5-cyanonicotinic acid 
• 1374969-97-7 6-(1H-benzo[d][1,2,3]traizol-1-yloxy)-2-(3-(2H-1,2,3-trazol-2-yl)phenylamino)-5-cyanonicotinamide 
• 1374969-98-8 2-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-6-((1R,2S)-2-tert-butyloxycarbonylaminocyclohexylamino)-5-cyanonicotinamide 
• 1374969-95-5 2-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-6-((1R,2S)-2-aminocyclohexylamino)-5-cyanonicotinamide 
• 1374970-09-8 2-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-6-((1R,2S)-2-aminocyclohexylamino)pyridine-3,5-dicarboxamide 
• 1374970-20-3 (R)-2-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-6-(1-amino-3-methyl-1-oxobutan-2-ylamino)-5-cyanonicotinamide 
• 1374969-75-1 C₂₃H₂₉FN₈O₃ 
• 1374970-30-5 C₂₅H₃₀N₈O₂ 
• 1374968-47-4 tert-butyl (1S,2R)-2-(3-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-4-cyanophenylamino)cyclohexylcarbamate 
• 1370261-95-2 tert-butyl (1S,2R)-2-(4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-5-carbamoylpyrimidin-2-ylamino)cyclohexylcarbamate 
• 1370261-98-5 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((1R, 2S)-2-aminocyclohexylamino)pyrimidine-5-carboxamide acetic acid salt 

Relevant academic research and scientific papers

Discovery of mercaptopropanamide-substituted aryl tetrazoles as new broad-spectrum metallo-β-lactamase inhibitors

β-Lactam antibiotic resistance mediated by metallo-β-lactamases (MBL) has threatened global public health. There are currently no available inhibitors of MBLs for clinical use. We previously reported the ruthenium-catalyzed meta-selective C-H nitration synthesis method, leading to some meta-mercaptopropanamide substituted aryl tetrazoles as new potent MBL inhibitors. Here, we described the structure-activity relationship of meta- and ortho-mercaptopropanamide substituted aryl tetrazoles with clinically relevant MBLs. The resulting most potent compound 13a showed IC50 values of 0.044 μM, 0.396 μM and 0.71 μM against VIM-2, NDM-1 and IMP-1 MBL, respectively. Crystallographic analysis revealed that 13a chelated to active site zinc ions via the thiol group and interacted with the catalytically important residues Asn233 and Tyr67, providing further structural information for the development of thiol based MBL inhibitors. This journal is

CYCLOHEXANEDIAMINE COMPOUNDS AND METHODS FOR THEIR PREPARATION

The present invention provides processes for the preparation of cyclohexanediamine compounds of formula Ia and intermediates thereof. The compounds are useful as Syk kinase inhibitors and in various pharmaceutical compositions, and particularly useful for treating conditions mediated at least in part by Syk kinase activity.

SELECTIVE KINASE INHIBITORS

Provided are pyrimidine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

3-AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The present invention relates to 3-azabicyclo[3.1.0]hexane derivatives, which are useful as vanilloid receptor (VR) ligands, methods of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.